Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. , located in San Francisco, US, specializes in developing innovative small molecule therapies to address chronic diseases, particularly autoimmune disorders, by modulating immune responses. Kezar Life Sciences, Inc. focuses on the development of therapies for chronic autoimmune diseases.

Founded in 2015, the company has pursued strategic funding initiatives and raised USD 50. 00 mn in a VENTURE DEBT round on February 4, 2020, bringing their total amount raised to USD 46. 70 mn. John Fowler serves as both the CEO and founder of the company.

Kezar Life Sciences is primarily focused on the development of innovative small molecule therapies aimed at regulating protein dysregulation that leads to chronic diseases, particularly autoimmune disorders. Their core product, Zetomipzomib (KZR-616), represents a first-in-class molecule designed to selectively inhibit the immunoproteasome, targeting specific cellular pathways involved in autoimmune conditions. The company aims to address limitations of traditional treatments by offering therapies that modulate the immune response rather than directly suppressing it. Kezar’s product offerings are geared towards healthcare providers and institutions engaged in the treatment of chronic autoimmune diseases, with the potential to serve patients in North America and Europe, among other regions.

Kezar Life Sciences generates revenue primarily through partnerships and collaborations with pharmaceutical companies and healthcare organizations involved in clinical trial development and product commercialization. The revenue structure may entail milestone payments and royalties derived from the successful development and commercialization of their flagship product, Zetomipzomib. Such transactions typically occur as the product progresses through various phases of clinical trials, leading to eventual market entry. While specific pricing plans for their products are not disclosed, the company’s financial model is designed to benefit from strategic partnerships that facilitate the delivery of breakthrough treatments to a global patient base.

Kezar Life Sciences is focused on continuing the development of Zetomipzomib and plans to explore additional new product candidates aimed at autoimmune diseases. The company seeks to expand its market presence, particularly in North America and Europe, by leveraging its recent VENTURE DEBT funding of USD 50. 00 mn to support ongoing clinical trials and product development initiatives. The company has successfully raised capital through various public offerings, including a USD 75.

00 mn IPO in June 2018 and additional funding rounds throughout 2020.